Panel members provide their own perspective on what clinical pathways encompass.
The discussion began with each of the panelists providing their unique perspective on clinical pathways.
Michael Fisch, MD, MPH, said that they are optimal care choices among a larger set of evidence-based choices that oncologists come across, although “they may not be as comprehensive as the guidelines developed by the [National Comprehensive Cancer Network].” His organization, AIM Specialty, is more focused on drug regimen treatment choices, he added, with emphasis is on efficacy and safety, with cost considered only when the first 2 features overlap for the treatments being compared.
Kathy Lokay concurred with Dr Fisch, adding that Via Oncology takes a slightly different approach that caters specifically to their customer base, which is primarily cancer centers. Our pathway development committee leans toward a more stratified pathway driven by a specific case presentation. She added that while pathways were “initiated on the medical oncology drug side, they lend themselves to virtually every aspect of cancer care,” including radiation oncology, surgical oncology, and symptom management. She emphasized that the intent of clinical pathways is to standardize the best evidence-based care.
“If you want to be a purist, in my way of thinking about it, the element that’s unique about pathways is a longitudinal characteristic,” said Robert Dubois, MD, PhD, unlike guidelines that work off of a single node.
According to Blaise Polite, MD, MPP, clinical pathways are a way to ensure some consistency in how we see patients “such that if a patient comes into my office or comes into one of my satellite’s offices with the same diagnosis, they’re not being treated in several different ways. It’s not whose door [patients] choose to open on that day and what appointment they get, but much more a consensus driven opinion by experts using evidence-based medicine.”
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome
April 19th 2024A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More